299 related articles for article (PubMed ID: 19105706)
21. Effects of high dose raloxifene in selected patients with advanced breast carcinoma.
Gradishar W; Glusman J; Lu Y; Vogel C; Cohen FJ; Sledge GW
Cancer; 2000 May; 88(9):2047-53. PubMed ID: 10813716
[TBL] [Abstract][Full Text] [Related]
22. Chemoprevention of breast cancer.
Thomsen A; Kolesar JM
Am J Health Syst Pharm; 2008 Dec; 65(23):2221-8. PubMed ID: 19020189
[TBL] [Abstract][Full Text] [Related]
23. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.
Ganz PA; Land SR
Menopause; 2008; 15(4 Suppl):797-803. PubMed ID: 18596601
[TBL] [Abstract][Full Text] [Related]
24. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.
Visvanathan K; Chlebowski RT; Hurley P; Col NF; Ropka M; Collyar D; Morrow M; Runowicz C; Pritchard KI; Hagerty K; Arun B; Garber J; Vogel VG; Wade JL; Brown P; Cuzick J; Kramer BS; Lippman SM;
J Clin Oncol; 2009 Jul; 27(19):3235-58. PubMed ID: 19470930
[TBL] [Abstract][Full Text] [Related]
25. Raloxifene in breast cancer prevention.
Gennari L; Merlotti D; Paola VD; Nuti R
Expert Opin Drug Saf; 2008 May; 7(3):259-70. PubMed ID: 18462184
[TBL] [Abstract][Full Text] [Related]
26. The use of tamoxifen and raloxifene for the prevention of breast cancer.
Wickerham DL; Costantino JP; Vogel VG; Cronin WM; Cecchini RS; Ford LG; Wolmark N
Recent Results Cancer Res; 2009; 181():113-9. PubMed ID: 19213563
[TBL] [Abstract][Full Text] [Related]
27. Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force.
Nelson HD; Smith ME; Griffin JC; Fu R
Ann Intern Med; 2013 Apr; 158(8):604-14. PubMed ID: 23588749
[TBL] [Abstract][Full Text] [Related]
28. Chemoprevention for high-risk women: tamoxifen and beyond.
Fabian CJ; Kimler BF
Breast J; 2001; 7(5):311-20. PubMed ID: 11906441
[TBL] [Abstract][Full Text] [Related]
29. Managing the risk of invasive breast cancer in women at risk for breast cancer and osteoporosis: the role of raloxifene.
Vogel VG
Clin Interv Aging; 2008; 3(4):601-9. PubMed ID: 19281053
[TBL] [Abstract][Full Text] [Related]
30. Selective estrogen receptor modulators and aromatase inhibitors for breast cancer chemoprevention.
Vogel VG
Curr Drug Targets; 2011 Dec; 12(13):1874-87. PubMed ID: 21158712
[TBL] [Abstract][Full Text] [Related]
31. The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials.
Martino S; Costantino J; McNabb M; Mershon J; Bryant K; Powles T; Secrest RJ
Oncologist; 2004; 9(2):116-25. PubMed ID: 15047916
[TBL] [Abstract][Full Text] [Related]
32. Chemoprevention of breast cancer: implications for postmenopausal women.
Fabian CJ; Kimler BF
Drugs Aging; 2002; 19(1):43-78. PubMed ID: 11929326
[TBL] [Abstract][Full Text] [Related]
33. Update on raloxifene to prevent endometrial-breast cancer.
Goldstein SR
Eur J Cancer; 2000 Sep; 36 Suppl 4():S54-6. PubMed ID: 11056320
[TBL] [Abstract][Full Text] [Related]
34. Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation.
Grady D; Ettinger B; Moscarelli E; Plouffe L; Sarkar S; Ciaccia A; Cummings S;
Obstet Gynecol; 2004 Oct; 104(4):837-44. PubMed ID: 15458908
[TBL] [Abstract][Full Text] [Related]
35. The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women.
Bevers TB
J Natl Compr Canc Netw; 2007 Sep; 5(8):719-24. PubMed ID: 17927929
[TBL] [Abstract][Full Text] [Related]
36. Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk.
Grady D; Cauley JA; Geiger MJ; Kornitzer M; Mosca L; Collins P; Wenger NK; Song J; Mershon J; Barrett-Connor E;
J Natl Cancer Inst; 2008 Jun; 100(12):854-61. PubMed ID: 18544744
[TBL] [Abstract][Full Text] [Related]
37. Drugs can reduce the incidence of breast cancer: now what?
Wozniak TF; Eppes PG; Wilson CT
Del Med J; 1999 Sep; 71(9):387-9. PubMed ID: 10584440
[No Abstract] [Full Text] [Related]
38. The selective estrogen receptor modulators in breast cancer prevention.
Li F; Dou J; Wei L; Li S; Liu J
Cancer Chemother Pharmacol; 2016 May; 77(5):895-903. PubMed ID: 26787504
[TBL] [Abstract][Full Text] [Related]
39. Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR).
Runowicz CD; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Ford LG; Vogel VG; Wolmark N
Am J Obstet Gynecol; 2011 Dec; 205(6):535.e1-5. PubMed ID: 21872200
[TBL] [Abstract][Full Text] [Related]
40. The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial.
Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Wolmark N
Clin Breast Cancer; 2002 Jun; 3(2):153-9. PubMed ID: 12123540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
